NCT07535632 2026-04-17
BEST
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
Clinical Trials
4 trialsNCT06992258 2026-03-17
FRUITION
Criterium, Inc.
Phase 2 Recruiting
NCT05343013 2026-03-06
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04109924 2026-02-10
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
Roswell Park Cancer Institute
Phase 2 Completed